Tempest Therapeutics, Inc. has reconvened its special meeting of stockholders to address critical governance amendments. The meeting, which originally began on July 27, 2026, aims to approve a Certificate of Amendment to the company’s Restated Certificate of Incorporation. This amendment seeks to replace specific supermajority voting requirements and allow stockholder action by written consent.

The importance of this meeting cannot be overstated, as it reflects Tempest's ongoing efforts to enhance shareholder engagement and streamline its governance processes. The reconvened meeting will take place on December 11, 2026, at 12:00 p.m. Eastern Time, via a live webcast.

Background

Tempest Therapeutics, Inc. operates in the pharmaceutical preparations sector, specifically under the SIC code 2834. The company is listed on the Nasdaq under the ticker symbol TPST. It is categorized as a non-accelerated filer and a smaller reporting company. Recent filings include a definitive proxy statement and various 8-K forms, indicating active engagement with its shareholders.

What the Filing Says

According to the filing dated November 16, 2026, a total of 11,052,422 shares, or 74.64% of the 14,806,997 shares of common stock outstanding as of May 28, 2026, were present at the meeting. However, there were not enough votes to approve the Proposal, prompting the decision to adjourn the meeting to allow for further participation.

Impact

This reconvened meeting may affect stockholders and potential investors in Tempest Therapeutics. The outcome of the vote could influence the company's governance structure and operational flexibility, impacting its future strategies and shareholder relations.

What's Next

The Special Meeting will reconvene on December 11, 2026, as stated in the filing. Stockholders can use the same access code as before to attend the meeting. Proxies previously submitted will be voted unless revoked, and no changes have been made to the Proposal.